The Pharmacy Service of Santiago de Compostela's University Hospital Complex (CHUS), alongside its healthcare and teaching responsibilities have committed to positioning clinical and translational research asone of its cornerstones. The Research and Innovation Unit (UII-FH) is part of the Pharmacy Service, accredited with ISO 9001:2015 since 2012. This unit is composed of clinicians, residents, and researchers with research and healthcare training spanning various fields of knowledge.

The know-how gained in diverse clinical areas and from the different fields encompassed by personalized medicine, allows us to actively participate in competitive research projects, clinical trials, and regional and national research structures.

The current healthcare research fields of UII-FH range from the individualized development of medications (FAR-GALenia), to the application of pharmacokinetic techniques to unveil the foundations of the variability in the response to drugs used in clinical practice (FAR-PRO-PKgen).

The research activities of the unit are coordinated from the Health Research Institute of Santiago de Compostela (IDIS). IDIS is a research center for innovation and technology transfer that optimizes existing synergies between the Integrated Management Area of Santiago de Compostela of the Galician Health Service (SERGAS) and the University of Santiago de Compostela (USC).

The institute is accredited by Carlos III Health Institute (ISCIII) as a National Health System (SNS) research center since 2010, and is one los núcleos centrales del Campus Vidaof the core units in “Campus Vida”, accredited as a Campus of International Excellence by the Ministry of Education, Culture and Sports since 2009

Researchers at UII-FH have received translational research training in different research groups, which has enabled the consolidation of lines of work of high interest in healthcare. Current research areas of UII-FH, span from individualized drug development (FAR-GALenia), in collaboration with the Clinical Pharmacology Group (IDIS), the Department of Pharmacology, Pharmacy and Pharmaceutical Technology (USC), and the Molecular Imaging Group (IDIS-CIMUS), to Personalized Medicine incorporating pharmacokinetic and pharmacogenetic techniques (FAR-PRO-PKgen), with the collaboration of the Genomic Medicine Group (IDIS, USC).

Finally, both areas converge in the field of independent clinical research (FAR-ICI), from which clinical trials aimed at analyzing the clinical the clinical impact of formulations and interventions developed in those areas are led.




The UII-FH has the support and funding from the Galician Innovation Agency (ACIS, GAIN), being recognized in 2020 as a group with growth potential (GPC) in the biosanitary research area.